The Effect of Pregabalin and Metformin on Subacute and Chronic Radiculopathy

Abstract

Background: Radicular pain is one of the most common forms of chronic pain in the world, which has challenges about effective medical therapy. The aim of this study was to evaluate the effect of pregabalin (PGB) and metformin (Met) on subacute and chronic radiculopathy. Materials and Methods: This double-blind prospective clinical trial was performed on 71 patients with subacute and chronic cervical and lumbosacral radiculopathy. Group A was treated with PGB 75 mg daily while Group B was treated with PGB 75 mg daily and Met 500 mg daily for 3 months. Finally, the pain score in both groups was evaluated based on visual analog scale (VAS) and numerical scale pain. Results: The results showed a significant reduction in VAS and pain severity in both groups but this reduction in the terms of VAS (47.79% vs. 46.48%, \( P = 0.125 \)) and pain severity (47.1% vs. 39.2%, \( P = 0.264 \)) was more in treated patients with PGB and Met as compared to PGB group while total pain experience (53.5% vs. 49.1%, \( P = 0.464 \)) and interference with daily function (57.1% vs. 50.61%, \( P = 0.726 \)) were more in patients treated with PGB alone. Conclusion: Our results showed that PGB and PGB + Met reduced pain intensity and interference with daily function while we did not observe significant differences between two groups. PGB alone would have the potentiality to become a simple and economic means to decrease radicular pain.

Keywords: Metformin, pregabalin, radicular pain

Introduction

Low back pain (LBP) is one of the most common musculoskeletal disorders which is experienced in approximately 80% of adults.\(^1\) Disc degeneration is one of the main reasons of chronic LBP (39%), which causes both biochemical and mechanical disorder that poses radiculopathy, a disorder caused by nerve root compression.\(^2\)

Radiculopathy is a challenging task with existing therapeutic choices.\(^3\) Many drugs are prescribed as treatment including nonsteroidal anti-inflammatory drugs, opioids, anticonvulsants, antidepressants, benzodiazepines, corticosteroids, muscle relaxants, and transdermal anesthetics, but few have been shown to be effective.\(^4\) Subacute or chronic radicular pain can negatively affect patient’s quality of life and ability to function his/her routine life. With appropriate treatment just one-fourth of patients with radicular pain receive a 50% relief from pain.\(^5\)

Pregabalin (PGB) is a structural analog of gamma-aminobutyric acid that selectively binds to alpha2-delta subunit of voltage-dependent calcium channels and poses analgesic, anxiolytic, and antiepileptic effects.\(^6\) In some studies, PGB has shown to have positive effects on pain relief and improving the component of pain and sleep disturbances in patients with peripheral diabetic neuropathy, postherpetic neuralgia, and spinal cord injury as a model of central neuropathic pain.\(^7,8\)

Furthermore, metformin (Met) has been used widely as an antidiabetic drug.\(^9\) Although the mechanism of Met action is not well clear, it has been recently suggested that Met has some pleiotropic actions, especially by affecting AMP-activated protein kinase (AMPK).\(^10\) Several roles of AMPK have been presented in diabetes mellitus, neuroprotection, anti-inflammation, and alteration of oxidative stress.\(^11,12\) Possibility of injury-induced neuropathic pain inhibition has been indicated for AMPK.\(^13\) Moreover, in a study of Taylor et al., Met use was associated with a decrease in lumbar radicular pain.\(^14\)

There is no information about comparison of PGB and Met in patients with radicular pain.
pain; therefore, this study was designed to evaluate effectiveness of PGB and Met on subacute and chronic radiculopathy.

**Materials and Methods**

**Study design and target group**

This double-blind prospective clinical trial was conducted in Neurology Department of Isfahan Alzahra and Kashani Hospitals, educational centers, from August 2014 to December 2015. The patients suffering from subacute (LBP for 4–8 weeks) and chronic (LBP for >8 weeks) cervical and lumbosacral radiculopathy receiving PGB (Group A) were compared to patients receiving PGB with Met (Group B). Inclusion criteria consisted of patients referred to Neurology Department of Alzahra and Kashani Hospitals with a diagnosis of subacute and chronic radiculopathy based on the international classification of diseases who has signed consent form to participate in the study and having age between 20 and 60 years. Exclusion criteria consisted of age <20 years or >60 years, dissatisfaction to continue participation in the study, improper use of drugs (PGB and Met), lose to follow-up due to various causes, comorbidity of diabetes and polyneuropathy, diabetic and other neuropathies, such as uremic, thyroid, liver, and B deficiency, consuming drugs effecting neuropathy such as gabapentin and tricyclic antidepressants, clinical Red flags of tumor and infection, creatinine >2.5, that is, contraindication of Met consumption, incidence of blurred vision, clumsiness confusion, and drowsiness due to PGB consumption.

**Participants**

The study flowchart is shown in Figure 1. Eighty patients with diagnosis of subacute and chronic cervical and lumbosacral radiculopathy, who had been diagnosed by a neurologist and based on inclusion and exclusion criteria, were included in the study. Subacute and chronic cervical and lumbosacral radiculopathy were diagnosed with clinical signs and symptoms and results of electromyography/neural conducting velocity.

All eligible patients were randomly divided into two groups using a block randomization procedure with matched patients in each block based on age and sex. Before administration, pain intensity was measured using visual analog scale (VAS) and numerical scale pain (NSP) [Tables 1 and 2]. Group A was treated with PGB 75 mg daily (Abidi Corp.) while Group B were treated with PGB 75 mg daily (Abidi Corp.) and Met 500 mg daily (Aria Corp.) for 3 months.

The study received ethics approval from the Ethics Committee of Isfahan University of Medical Sciences, and

| Table 1: Numerical scale pain for pain comparing at beginning and within 3 months |
|-----------------------------------------------|
| **Pain scale**               | **Score** |
| Pain characteristics           | None=0    |
| Throbbing                      | Mild=1    |
| Shooting                        | Moderate=2 |
| Stabbing                       | Severe=3  |
| Sharp                          |           |
| Cramping                       |           |
| Gnawing                        |           |
| Hot/burning                    |           |
| Aching                         |           |
| Heavy                          |           |
| Tender                         |           |
| Splitting                      |           |
| Tiring/exhausting              |           |
| Sickening                      |           |
| Fearful                        |           |
| Punishing                      |           |
| Pain now                       | 0-10      |
| Total pain experience          | 0-10      |
| Interference with daily function | None=0  |
| General activity               | Mild=1    |
| Distressing                    | Discomforting=2 |
| Horrible                       | Excruciating=5 |
| Enjoyment of life              | 0-3=does not interfere |
| Ability to concentrate         | 4.5=completely interfere |
| Appetite                       |           |
all participants filled written informed consent. Finally, VAS and NSP \(^{12}\) were measured after 3 months of intervention in both groups.

As Met reduces the level of Vitamin B\(_{12}\), we checked serum levels of Vitamin B\(_{12}\) before and after intervention in Group B. If the serum levels of Vitamin B\(_{12}\) were lower than normal, we treat patients after intervention with folic acid.

**Data analysis**

Data were analyzed and reported only for patients who completed the trial. Statistical analysis of data was performed using IBM SPSS version 22, United States software. To compare qualitative variables, Chi-square test was used. Normal distribution of all studied parameters was checked with Kolmogorov–Smirnov test. Student’s t-test and paired t-test were used for variables which were in a normal distribution, besides Mann–Whitney and Wilcoxon test were used for variables that were not in normal distribution. \(P < 0.05\) was considered statistically significant.

**Results**

In this study, total number of 79 patients was participated in the study. Eight patients excluded due to incidence of PGB side effects such as drowsiness. Thirty-five patients were in PGB group and 36 were in PGB plus Met group. Demographic features in terms of age (\(P = 0.781\), sex (\(P = 0.737\)), body mass index (\(P = 0.667\)), duration of pain (\(P = 0.619\)), pain characteristic (\(P = 0.513\)), and interference with daily function (\(P = 0.169\)) in both groups were similar. While VAS (6.8 vs. 5.4, \(P < 0.001\)), pain severity (2.76 vs. 2.5, \(P = 0.048\)), and total pain experience (3.36 vs. 2.71, \(P < 0.001\)) in patients treated with PGB and Met were significantly higher as compared to PGB group [Table 3].

As obtained, after 3-month intervention, VAS, pain severity, total pain experience, and interference with daily function were significantly decreased in both groups (\(P < 0.001\)) [Tables 4 and 5]; however, we did not observe significant differences between the groups [Table 6]. Moreover, by analyzing mean changing score in terms of VAS, pain severity, total pain experience, and interference with daily function, no significant differences were observed between groups. However, reduction rate in these subunits in both groups was significant but this reduction in terms of VAS (47.79% vs. 46.48%) and pain severity (47.1% vs. 39.2%) was more in patients treated with PGB and Met as compared to PGB group while reduction in total pain experience (53.5% vs. 49.1%) and interference with daily function (57.1% vs. 50.61%) was more in patients treated with PGB alone; however, these differences were not statistically significant.

**Discussion**

The results of the present study about mean changing score in terms of VAS, pain severity, total pain experience, and

| Table 2: Visual analog scale for pain comparing at beginning and within 3 months |
|-----------------------------|----------------|----------------|----------------|
| Score | Duration | Score Intensity | Score Frequency |
| 4 | >15 min | 1 | Once at night | 2 | Three times a week |
| 2 | Between 5 and 15 min | 2 | More than once at night | 3 | Most nights |
| 1 | <5 min | 4 | Every night |

| Table 3: Studied variables before intervention in both PGB and PGB with Met groups |
|-----------------------------|----------------|----------------|----------------|
| Group variables | PGB | PGB+Met | \(P\) |
| Age (year) | 44.12±11.86 | 42.25±12.9 | 0.781 |
| Sex (Male) (%) | 23 (65.7) | 25 (69.4) | 0.737 |
| BMI (kg/m\(^2\)) | 30.02±5.4 | 29.5±4.9 | 0.667 |
| Duration of pain (years) | 8.14±2.84 | 8.44±2.22 | 0.619 |
| VAS | 5.4±1.53 | 6.8±1.58 | <0.001 |
| Pain characteristic | | | |
| Throbbing (%) | 1 (3.2) | 0 | 0.513 |
| Shooting (%) | 6 (19.4) | 6 (19.4) | |
| Stabbing (%) | 1 (3.2) | 4 (12.9) | |
| Sharp (%) | 0 | 1 (3.2) | |
| Cramping (%) | 20 (64.5) | 17 (54.8) | |
| Hot/burning (%) | 0 | 1 (3.2) | |
| Aching (%) | 3 (9.7) | 2 (6.5) | |
| Pain severity in NSP | 2.5±0.65 | 2.76±0.42 | 0.048 |
| Total pain experience in NSP | 2.71±0.75 | 3.36±0.68 | <0.001 |
| Interference with daily function in NSP | 3.8±0.86 | 4.05±0.67 | 0.169 |

| Table 4: Mean differences in studied variables in PGB group |
|-----------------------------|----------------|----------------|----------------|
| Variables | Mean | SD | 95% confidence interval of the difference | \(t\) | df | Sig |
| VAS | 2.51 | 1.66 | 1.94 | 3.08 | 8.911 | 34 | <0.001 |
| Pain severity in NSP | 0.98 | 1.44 | 0.48 | 1.48 | 4.029 | 34 | <0.001 |
| Total pain experience in NSP | 1.45 | 1.01 | 1.11 | 1.8 | 8.535 | 34 | <0.001 |
| Interference with daily function in NSP | 2.17 | 1.31 | 1.71 | 2.62 | 9.754 | 34 | <0.001 |

interference with daily function, have not shown significant differences between patients receiving PGB and PGB with Met. However, reduction rate in these subunits in both groups was significant but this reduction in terms of VAS (47.79% vs. 46.48%) and pain severity (47.1% vs. 39.2%) was more in patients treated with PGB alone; however, these differences were not statistically significant.
Table 5: Mean differences in studied variables in PGB with Met group

| Variables                          | Mean | SD  | 95% confidence interval of the difference | t     | df  | Sig   |
|------------------------------------|------|-----|------------------------------------------|-------|-----|-------|
| VAS                                | 3.25 | 2.27|                                          | 4.01  | 8.581 | 35    |
| Pain severity in NSP               | 1.3  | 0.88|                                          | 1.6   | 8.815 | 35    |
| Total pain experience in NSP       | 1.65 | 1.21|                                          | 2.06  | 8.143 | 35    |
| Interference with daily function in NSP | 2.05 | 1.45|                                          | 1.56  | 8.488 | 35    |

Table 6: Studied variables 3 months after intervention in both PGB and PGB with Met groups

| Group variables                             | PGB            | PGB+Met       | P   |
|---------------------------------------------|----------------|---------------|-----|
| VAS                                         | 2.88±1.72      | 3.55±2.13     | 0.151|
| Pain severity in NSP                        | 1.51±1.76      | 1.45±0.78     | 0.863|
| Total pain experience in NSP                | 1.25±0.81      | 1.7±1.23      | 0.073|
| Interference with daily function in NSP     | 1.62±1.33      | 2±1.43        | 0.262|

Table: Mean differences in studied variables in PGB with Met group

To PGB group while total pain experience (53.5% vs. 49.1%) and interference with daily function (57.1% vs. 50.61%) were more in patients treated with PGB alone.

There are few trials which have assessed pharmacological management of subacute and chronic radiculopathy. Our data appear to be the first in which PGB with Met has been used for the management of cervical and lumbosacral radiculopathy. Our findings suggest that both PGB alone and PGB with Met can be effective in decreasing radicular symptoms and pain, patient disability, and improvement of patient’s quality of life.

Monotherapy with PGB, or as an add-on therapy such as Met, caused a very marked decrease in pain (over 50%). The proportion of responders in this study, 46.48% and 47.79% in monotherapy (PGB) and add-on (PGB + Met) groups, respectively, was at least similar to study which administrated PGB only among patients with diabetic neuropathy (39 and 48%),[7,8] postherpetic neuralgia (28 and 75%),[17,18] and patients with central neuropathic pain associated with spinal cord injury (22%).[19]

Moreover, we found improvement in interference with daily function in both groups, but a little more in PGB group. Due to frequent co-occurrence of sleep disturbances, enjoyment, concentration, and mood decrease in such patients,[20] PGB may have positive role in such situations.

Adding Met did not decrease pain severity based on VAS and NSP. As observed, PGB alone had the same effect in decreasing pain intensity. However, many studies showed similar results, Taylor et al. presented that Met therapy is associated with a decrease in severity of lumbar radicular pain.[21]

Moreover, our results are in accordance with some other mechanistic studies from preclinical models which have demonstrated a powerful antihyperalgesic/antiallodynic effect of Met and other AMPK activators on chronic pain,[21,22] and a recent case report suggesting efficacy of Met in humans.[23]

These differences between our results and mentioned studies may be due to different sample size, demographic features of studied population, the dosage of Met, and excluding diabetic patients, which did not perform in mentioned studies. Consequently, our results are more close to reality by eliminating diabetic patients.

Conclusion

Our results showed that both PGB alone and PGB + Met reduced pain intensity and interference with daily function while we did not observe significant differences between two groups. PGB alone would have the potentiality to become a simple and economic means to decrease radicular pain. A large-scale study is needed to come to clinical guidelines and recommendation for neurologist and neurosurgeries.

Acknowledgment

We gratefully acknowledge the dedicated efforts of the investigators, coordinators, volunteer patients who participated in this study, and the Clinical Research Development Units of Isfahan Alzahra Hospital.

Financial support and sponsorship

This study was financially supported by Vice-Chancellor for research and technology of Isfahan University of Medical Sciences (Grant number: 394639).

Conflicts of interest

There are no conflicts of interest.

References

1. Furlan AD, Giraldo M, Baskwill A, Irvin E, Imamura M. Massage for low-back pain. Cochrane Database Syst Rev 2015;(9):CD001929.
2. Anderson DG, Tannoury C. Molecular pathogenic factors in symptomatic disc degeneration. Spine J 2005;5 6 Suppl: 260S-6S.
3. Jarvik JG, Hollingsworth W, Heagerty PJ, Haynor DR, Boyko EJ, Deyo RA. Three-year incidence of low back pain in an initially asymptomatic cohort: Clinical and imaging risk factors. Spine (Phila Pa 1976) 2005;30:1541-8.
4. Pinto RZ, Maher CG, Ferreira ML, Ferreira PH, Hancock M, Oliveira VC, et al. Drugs for relief of pain in patients with sciatica: Systematic review and meta-analysis. BMJ 2012;344:e497.
5. Nightingale S. The neuropathic pain market. Nat Rev Drug Discov 2012;11:101-2.
6. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: A novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007;29:26-48.

7. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain 2005;6:253-60.

8. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-63.

9. van Seventer R, Feister HA, Young JP Jr., Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: A 13-week, randomized trial. Curr Med Res Opin 2006;22:375-84.

10. Kruszewski SP, Shane JA. Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial. Neurology 2007;68:2158-9.

11. Ma J, Yu H, Liu J, Chen Y, Wang Q, Xiang L. Metformin attenuates hyperalgesia and allodynia in rats with painful diabetic neuropathy induced by streptozotocin. Eur J Pharmacol 2015;764:599-606.

12. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009;89:1025-78.

13. Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract 2011;93:56-62.

14. Salminen A, Hyttinen JM, Kaarniranta K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: Impact on healthspan and lifespan. J Mol Med (Berl) 2011;89:667-76.

15. Taylor A, Westveld AH, Szkudlinska M, Guruguri P, Annabi E, Patwardhan A, et al. The use of metformin is associated with decreased lumbar radiculopathy pain. J Pain Res 2013;6:755-63.

16. Staal JB, Nelemans PJ, de Bie RA. Spinal injection therapy for low back pain. JAMA 2013;309:2439-40.

17. Sabatowski R, Gálvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial. Pain 2004;109:26-35.

18. Achar A, Chakraborty PP, Bisai S, Biswas A, Guharay T. Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia. Acta Dermatovenerol Croat 2012;20:89-94.

19. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial. Neurology 2006;67:1792-800.

20. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: A novel treatment approach. Clin J Pain 2007;23:15-22.

21. Price TJ, Dussor G. AMPK: An emerging target for modification of injury-induced pain plasticity. Neurosci Lett 2013;557(Pt A):9-18.

22. Melemedjian OK, Yassine HN, Shy A, Price TJ. Proteomic and functional annotation analysis of injured peripheral nerves reveals ApoE as a protein upregulated by injury that is modulated by metformin treatment. Mol Pain 2013;9:14.

23. Labuzek K, Liber S, Marcel W, Okopien B. Controlling newly diagnosed type 2 diabetes mellitus with metformin managed pain symptoms in a patient affected with Dercum’s disease. Pain Med 2012;13:1526-7.